Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention

Table 4 Chemotherapy (paclitaxel) dose changes during hilotherapy treatment

	Patients, n (%)
Completed scheduled CP cycle1	37 (84.1)
Paclitaxel dose reduction/discontinuation	9 (20)
Reason for Paclitaxel reduction/discontinuation	3 (6.8) hematological toxicity; 3 (6.8) disease progression; 2 (4.5) paclitaxel allergic reaction; 1 (2.2) CIPN ≥ 2

¹Carboplatin area under the curve 5 mg/mL per min plus paclitaxel at 175 mg/mq every 3 wk.

CP: Carboplatin/paclitaxel; CIPN: Chemotherapy-induced peripheral neuropathy.